VEGFA and hepatocellular carcinoma: Sorafenib, a multi-kinase inhibitor targeting vascular endothelial growth factor, was the first molecular targeted drug approved for systemic HCC therapy and remains the standard first-line treatment for patients with unresectable or advanced disease (Llovet et al., 2008; Tang et al., 2020).